Maravai LifeSciences (MRVI) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 124.5% versus a gain of 74.8%. Over five years, RCUS leads with a -28.7% price change compared with -80.0% for MRVI. Arcus Biosciences is the larger company by market cap ($3.08 billion vs $2.71 billion), about 1.1 times the size.
Maravai LifeSciences converts more of its revenue into profit, with a net margin of -70.4% versus -142.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRVI | RCUS |
|---|---|---|
| Share price | $7.31 | $24.52 |
| Market cap | $2.71B | $3.08B |
| 1-day change | -1.62% | +0.99% |
| YTD return | +128.62% | +2.90% |
| 1-year return | +124.47% | +74.77% |
| 5-year return | -79.97% | -28.70% |
| EPS (TTM) | $-0.53 | $-3.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $185.74M | $247.00M |
| Revenue growth (YoY) | -28.34% | -4.26% |
| Net income (latest FY) | $-130.77M | $-353.00M |
| Gross margin | 18.30% | — |
| Operating margin | -115.89% | -156.28% |
| Net margin | -70.41% | -142.91% |
| 52-week high | $9.42 | $31.74 |
| 52-week low | $2.55 | $14.26 |
| Distance from 52-week high | -22.40% | -22.74% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +7.11% | +62.77% |
| Average volume | 3.33M | 1.32M |
| Shares outstanding | 148.99M | 125.77M |
| Employees | 415 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed RCUS by 49.7 percentage points over the past year.
- Maravai LifeSciences is more profitable, keeping -70.4 cents of every revenue dollar as net income versus -142.9 cents for Arcus Biosciences.
- Arcus Biosciences grew revenue faster in its latest fiscal year (-4.26% vs -28.34%).
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
MRVI vs RCUS FAQ
Which is bigger, Maravai LifeSciences or Arcus Biosciences?
Arcus Biosciences (RCUS) is larger, with a market capitalization of $3.08B compared with $2.71B for Maravai LifeSciences (MRVI).
Which stock has performed better over the past year, MRVI or RCUS?
MRVI returned +124.47% over the past 12 months, compared with +74.77% for RCUS (price return, excluding dividends). Past performance does not predict future results.
Are Maravai LifeSciences and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.